Product: Fibronectin Antibody
Catalog: AF5335
Source: Rabbit
Application: WB, IHC, IF/ICC, ELISA(peptide)
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Sheep, Rabbit
Mol.Wt.: 263 kD, 200 kD; 272kD(Calculated).
Uniprot: P02751
RRID: AB_2837820

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
Reactivity:
Human,Mouse,Rat
Prediction:
Pig(92%), Bovine(100%), Sheep(92%), Rabbit(100%)
Clonality:
Polyclonal
Specificity:
Fibronectin Antibody detects endogenous levels of total Fibronectin.
RRID:
AB_2837820
Cite Format: Affinity Biosciences Cat# AF5335, RRID:AB_2837820.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CIG; Cold insoluble globulin; Cold-insoluble globulin; DKFZp686F10164; DKFZp686H0342; DKFZp686I1370; DKFZp686O13149; ED B; Fibronectin 1; FINC; FINC_HUMAN; FN; FN1; FNZ; GFND; GFND2; LETS; Migration stimulating factor; MSF; Ugl-Y3;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P02751 FINC_HUMAN:

Expressed in the inner limiting membrane and around blood vessels in the retina (at protein level) (PubMed:29777959). Plasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular FN (dimeric or cross-linked multimeric forms), made by fibroblasts, epithelial and other cell types, is deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine (PubMed:17614963).

Description:
Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization
Sequence:
MLRGPGPGLLLLAVQCLGTAVPSTGASKSKRQAQQMVQPQSPVAVSQSKPGCYDNGKHYQINQQWERTYLGNALVCTCYGGSRGFNCESKPEAEETCFDKYTGNTYRVGDTYERPKDSMIWDCTCIGAGRGRISCTIANRCHEGGQSYKIGDTWRRPHETGGYMLECVCLGNGKGEWTCKPIAEKCFDHAAGTSYVVGETWEKPYQGWMMVDCTCLGEGSGRITCTSRNRCNDQDTRTSYRIGDTWSKKDNRGNLLQCICTGNGRGEWKCERHTSVQTTSSGSGPFTDVRAAVYQPQPHPQPPPYGHCVTDSGVVYSVGMQWLKTQGNKQMLCTCLGNGVSCQETAVTQTYGGNSNGEPCVLPFTYNGRTFYSCTTEGRQDGHLWCSTTSNYEQDQKYSFCTDHTVLVQTRGGNSNGALCHFPFLYNNHNYTDCTSEGRRDNMKWCGTTQNYDADQKFGFCPMAAHEEICTTNEGVMYRIGDQWDKQHDMGHMMRCTCVGNGRGEWTCIAYSQLRDQCIVDDITYNVNDTFHKRHEEGHMLNCTCFGQGRGRWKCDPVDQCQDSETGTFYQIGDSWEKYVHGVRYQCYCYGRGIGEWHCQPLQTYPSSSGPVEVFITETPSQPNSHPIQWNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPVTSNTVTGETTPFSPLVATSESVTEITASSFVVSWVSASDTVSGFRVEYELSEEGDEPQYLDLPSTATSVNIPDLLPGRKYIVNVYQISEDGEQSLILSTSQTTAPDAPPDTTVDQVDDTSIVVRWSRPQAPITGYRIVYSPSVEGSSTELNLPETANSVTLSDLQPGVQYNITIYAVEENQESTPVVIQQETTGTPRSDTVPSPRDLQFVEVTDVKVTIMWTPPESAVTGYRVDVIPVNLPGEHGQRLPISRNTFAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQTTKLDAPTNLQFVNETDSTVLVRWTPPRAQITGYRLTVGLTRRGQPRQYNVGPSVSKYPLRNLQPASEYTVSLVAIKGNQESPKATGVFTTLQPGSSIPPYNTEVTETTIVITWTPAPRIGFKLGVRPSQGGEAPREVTSDSGSIVVSGLTPGVEYVYTIQVLRDGQERDAPIVNKVVTPLSPPTNLHLEANPDTGVLTVSWERSTTPDITGYRITTTPTNGQQGNSLEEVVHADQSSCTFDNLSPGLEYNVSVYTVKDDKESVPISDTIIPEVPQLTDLSFVDITDSSIGLRWTPLNSSTIIGYRITVVAAGEGIPIFEDFVDSSVGYYTVTGLEPGIDYDISVITLINGGESAPTTLTQQTAVPPPTDLRFTNIGPDTMRVTWAPPPSIDLTNFLVRYSPVKNEEDVAELSISPSDNAVVLTNLLPGTEYVVSVSSVYEQHESTPLRGRQKTGLDSPTGIDFSDITANSFTVHWIAPRATITGYRIRHHPEHFSGRPREDRVPHSRNSITLTNLTPGTEYVVSIVALNGREESPLLIGQQSTVSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTNIDRPKGLAFTDVDVDSIKIAWESPQGQVSRYRVTYSSPEDGIHELFPAPDGEEDTAELQGLRPGSEYTVSVVALHDDMESQPLIGTQSTAIPAPTDLKFTQVTPTSLSAQWTPPNVQLTGYRVRVTPKEKTGPMKEINLAPDSSSVVVSGLMVATKYEVSVYALKDTLTSRPAQGVVTTLENVSPPRRARVTDATETTITISWRTKTETITGFQVDAVPANGQTPIQRTIKPDVRSYTITGLQPGTDYKIYLYTLNDNARSSPVVIDASTAIDAPSNLRFLATTPNSLLVSWQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNNQKSEPLIGRKKTDELPQLVTLPHPNLHGPEILDVPSTVQKTPFVTHPGYDTGNGIQLPGTSGQQPSVGQQMIFEEHGFRRTTPPTTATPIRHRPRPYPPNVGEEIQIGHIPREDVDYHLYPHGPGLNPNASTGQEALSQTTISWAPFQDTSEYIISCHPVGTDEEPLQFRVPGTSTSATLTGLTRGATYNVIVEALKDQQRHKVREEVVTVGNSVNEGLNQPTDDSCFDPYTVSHYAVGDEWERMSESGFKLLCQCLGFGSGHFRCDSSRWCHDNGVNYKIGEKWDRQGENGQMMSCTCLGNGKGEFKCDPHEATCYDDGKTYHVGEQWQKEYLGAICSCTCFGGQRGWRCDNCRRPGGEPSPEGTTGQSYNQYSQRYHQRTNTNVNCPIECFMPLDVQADREDSRE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
100
Bovine
100
Pig
92
Sheep
92
Xenopus
50
Horse
0
Dog
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P02751 As Substrate

Site PTM Type Enzyme
S41 Phosphorylation
Y101 Phosphorylation
Y106 Phosphorylation
Y112 Phosphorylation
T136 Phosphorylation
T278 O-Glycosylation
T279 O-Glycosylation
S280 O-Glycosylation
S281 O-Glycosylation
S283 O-Glycosylation
T287 O-Glycosylation
Y372 Phosphorylation
N430 N-Glycosylation
K486 Methylation
N528 N-Glycosylation
N542 N-Glycosylation
Y588 Phosphorylation
Y641 Phosphorylation
T715 Phosphorylation
N877 N-Glycosylation
S904 Phosphorylation
S909 Phosphorylation
Y937 Phosphorylation
T960 Phosphorylation
S968 Phosphorylation
T972 Phosphorylation
K987 Acetylation
N1007 N-Glycosylation
Y1042 Phosphorylation
K1050 Ubiquitination
Y1206 Phosphorylation
N1244 N-Glycosylation
T1271 Phosphorylation
T1276 O-Glycosylation
S1565 O-Glycosylation
S1566 O-Glycosylation
S1567 O-Glycosylation
T1570 O-Glycosylation
T1641 O-Glycosylation
T1743 Phosphorylation
T1762 Phosphorylation
T1786 Phosphorylation
S1833 Phosphorylation
K1837 Ubiquitination
T1840 Phosphorylation
T1842 Phosphorylation
T1855 Phosphorylation
T1860 Phosphorylation
Y1879 Phosphorylation
K1880 Acetylation
Y1884 Phosphorylation
S1982 Phosphorylation
T1999 O-Glycosylation
T2060 O-Glycosylation
T2061 O-Glycosylation
T2064 O-Glycosylation
T2065 O-Glycosylation
T2067 O-Glycosylation
N2108 N-Glycosylation
Y2258 Phosphorylation
Y2312 Phosphorylation
S2318 Phosphorylation
S2341 O-Glycosylation
S2341 Phosphorylation
T2345 O-Glycosylation
T2346 O-Glycosylation
S2349 O-Glycosylation
S2349 Phosphorylation
Y2350 Phosphorylation
Y2353 Phosphorylation
S2354 Phosphorylation
T2363 Phosphorylation
S2384 Phosphorylation

Research Backgrounds

Function:

Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, and maintenance of cell shape. Involved in osteoblast compaction through the fibronectin fibrillogenesis cell-mediated matrix assembly process, essential for osteoblast mineralization. Participates in the regulation of type I collagen deposition by osteoblasts.

Anastellin binds fibronectin and induces fibril formation. This fibronectin polymer, named superfibronectin, exhibits enhanced adhesive properties. Both anastellin and superfibronectin inhibit tumor growth, angiogenesis and metastasis. Anastellin activates p38 MAPK and inhibits lysophospholipid signaling.

PTMs:

Sulfated.

It is not known whether both or only one of Thr-2155 and Thr-2156 are/is glycosylated.

Forms covalent cross-links mediated by a transglutaminase, such as F13A or TGM2, between a glutamine and the epsilon-amino group of a lysine residue, forming homopolymers and heteropolymers (e.g. fibrinogen-fibronectin, collagen-fibronectin heteropolymers).

Phosphorylated by FAM20C in the extracellular medium.

Proteolytic processing produces the C-terminal NC1 peptide, anastellin.

Some lysine residues are oxidized to allysine by LOXL3, promoting fibronectin activation and matrix formation.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in the inner limiting membrane and around blood vessels in the retina (at protein level). Plasma FN (soluble dimeric form) is secreted by hepatocytes. Cellular FN (dimeric or cross-linked multimeric forms), made by fibroblasts, epithelial and other cell types, is deposited as fibrils in the extracellular matrix. Ugl-Y1, Ugl-Y2 and Ugl-Y3 are found in urine.

Subunit Structure:

Mostly heterodimers or multimers of alternatively spliced variants, connected by 2 disulfide bonds near the carboxyl ends; to a lesser extent homodimers. Interacts with FBLN1, AMBP, TNR, LGALS3BP and COL13A1. Interacts with FBLN7 (By similarity). Interacts with COMP. Interacts with TNR; the interaction inhibits cell adhesion and neurite outgrowth (By similarity). Interacts with FST3 and MYOC.

(Microbial infection) Interacts with S.aureus FnbA.

(Microbial infection) Interacts with M.bovis FbpB via the collagen-binding region.

(Microbial infection) Interacts with recombinant S.pneumoniae PavA (rqcH).

(Microbial infection) Interacts with recombinant S.suis FbpS (rqcH) via fibronectin's N-terminal 30 kDa region.

(Microbial infection) Interacts with fibronectin-binding proteins from other Mycobacteria.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > ECM-receptor interaction.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

References

1). Xiong J et al. Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma. Cancer Cell 2020 Mar 16;37(3):403-419 (PubMed: 32183952) [IF=38.585]

Application: IF/ICC    Species: human    Sample: NK-92 cells

Figure 6. Biological Function of MGA and BRDT. (D) Immunofluorescence images of E-cadherin (green), fibronectin (red), or vimentin (red) in NK-92 cells transfected with MGA shRNAs or scramble. Cells were counterstained with DAPI (blue). (G) Immunofluorescence images of E-cadherin (green), fibronectin (red), or vimentin (red) in NK-92 cells transfected with pCMV6-BRDT (upper panel) or vector control (lower panel). Cells were counterstained with DAPI (blue).

2). Tian Y et al. Huaier polysaccharides suppress triple-negative breast cancer metastasis and epithelial-mesenchymal transition by inducing autophagic degradation of Snail. Cell Biosci 2021 Sep 4;11(1):170. (PubMed: 34481526) [IF=7.133]

Application: WB    Species: human    Sample: breast cancer cells

Fig. 1| PS-T inhibits invasion, migration and EMT in breast cancer cells in vitro and in vivo. d 4 T-1 and MDA-MB-231 cells are treated with 5 μg/mL PS-T for 24 h. The levels of each EMT marker are quantifed using the NIH ImageJ software. (mean ± SD, *P < 0.05 and **P < 0.01)

3). Li X et al. Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-β1 pathway. Eur J Med Chem 2018 Aug 3;157:229-247 (PubMed: 30096654) [IF=7.088]

4). Li X et al. Betulinic acid Attenuated Bleomycin-induced Pulmonary Fibrosis by Effectively Intervening Wnt/β-catenin Signaling. Phytomedicine 2021 Jan;81:153428. (PubMed: 33341025) [IF=6.656]

5). Li X et al. Bergenin attenuates bleomycin‐induced pulmonary fibrosis in mice via inhibiting TGF‐β1 signaling pathway. Phytother Res 2021 Aug 10. (PubMed: 34375009) [IF=6.388]

6). Li X et al. Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β signaling via targeting HSP90β. Biochem Pharmacol 2020 Jun 11;114097. (PubMed: 32535102) [IF=6.100]

7). Wu Y et al. Biomimetic titanium implant coated with extracellular matrix enhances and accelerates osteogenesis. Nanomedicine (Lond) 2020 Jul 24. (PubMed: 32705940) [IF=6.096]

Application: IF/ICC    Species: Rabbit    Sample:

Figure 7. The binding ability of extracellular matrix to titanium-modified surfaces. (A) The total collagen content of the ECM-coated titanium-modified surface after UV irradiation was detected by using a conventional hydroxyproline assay. *p < 0.05; **p < 0.01. (B) Alizarin red staining was used to analyze the mineralization of the ECM-coated titanium-modified surface after UV irradiation. The calcifying nodules were shown by green arrows. (C) The fibronectin on the ECM-coated titanium-modified surface after UV treatment was detected by immunofluorescence. The fibronectin was indicated in green. (D) The topography of the biomimetic titanium implant before screwing into bone (a–c) and after implant removal from bone (d–f) (50,000× magnification). (a) and (d) represent the ECM-Ctrl group, (b) and (e) represent the ECM-SLA group, and (c) and (f) represent the ECM-TNT group. Control: Polishing titanium implant; ECM-Ctrl: Polishing titanium implant coated with extracellular matrix; ECM-SLA: Sand blasting and etching treated titanium implant coated with extracellular matrix; ECM-TNT: TiO2 nanotube topography implant coated with extracellular matrix; SLA: Sand blasting and etching treated titanium implant; TNT: TiO2 nanotube topography implant; UV: Ultraviolet.

8). Yang Y et al. A Testis-Derived Hydrogel as an Efficient Feeder-Free Culture Platform to Promote Mouse Spermatogonial Stem Cell Proliferation and Differentiation. Front Cell Dev Biol 2020 May 19;8:250. (PubMed: 32509769) [IF=6.081]

Application: IHC    Species: mice    Sample: Testis

FIGURE 2 | Immunohistochemical staining of native testis and decellularized testicular matrix (DTM). (A) Immunohistochemical validation of the essential extracellular matrix proteins of the native testis (laminin, collagen type I, collagen type IV, and fibronectin) in the DTM. Scale bar, 200 µm. (B–E) Relative quantity of collagen I, collagen IV, fibronectin, and laminin. ImageJ software was used to determine the average optical density (AOD). Data were shown as mean ± SD, n = 8. Differences were considered statistically significant at *p < 0.05, **p < 0.01.

9). Li X et al. Ellagic Acid Attenuates BLM-Induced Pulmonary Fibrosis via Inhibiting Wnt Signaling Pathway. Front Pharmacol 2021 Apr 12;12:639574. (PubMed: 33912053) [IF=5.810]

Application: IHC    Species: mice    Sample: lung tissue

FIGURE 6 Ellagic acid attenuates BLM-induced fibroblasts activation and ECM accumulation in vivo. The mice were treated with Ellagic acid (10 mg/kg, 20 mg/kg) from day 7–13 after administrating BLM (A) Immunohistochemistry was used to analyze the expression levels of α-SMA, Col1 and Fn (n = 3). Quantitative analysis was shown beside. Scale bars: 50 μm (B–C) The expression levels of α-SMA and Col1 were detected by immunofluorescence in lung sections. The analyses of mean gray value were shown beside. Scale bars: 50 μm (D) Lung homogenization was used to analysis the α-SMA, LC3-II/I and p-mTOR (S2248), mTOR expression levels by Western blot (n = 6). Densitometric analyses were shown beside. Data in (A,D) are means ± Standard Error of Mean, *p < 0.05, **p < 0.01, ***p < 0.001, and NS: nonsignificant (one-way ANOVA). β-tubulin was used as a loading control.

10). Li X et al. Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice. Front Pharmacol 2019 Sep 13;10:1021 (PubMed: 31572194) [IF=5.810]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.